PONENTE study

The UNC AAP is participating in PONENTE, a multi-center study designed to evaluate the efficacy and safety of reducing daily oral corticosteroids after initiation of benralizumab (Fasenra) administered subcutaneously in patients with severe eosinophilic asthma.